Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook insights.citeline.com//scrip/busines…

In this episode: Madrigal regains MASH lead with EU Rezdiffra approval; Viking’s obesity data scare investors; China assets lead GLP-1 deals; CSL and others restructure; and Indegene exec on DTP and MFN policies.

An interview with OneSource CEO, MD Neeraj Sharma reveals he isn't just counting on semaglutide (Novo's Wegovy, Ozempic) but is talking to next-gen GLP-1 innovators for growth #BusinessNews #Strategy Strides Pharma Science Limited insights.citeline.com//scrip/leaders…

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray. This is what we had said. Now 50% tariffs come into effect from Aug. 27 as US Customs issues notice #TariffsOnIndia #Tariffs #TradeWar #BusinessStrategy insights.citeline.com//pink-sheet/ma…

A Decade Of Transformation: Dong-A ST Readies For Take Off As An Innovative Pharma — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/44pde vist.ly/44pdf

Dong-A ST’s head of research talks to Scrip, Citeline Commercial about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential. insights.citeline.com/scrip/leadersh…

Join Jung Won Shin in her latest Korean-language mini #podcast for Citeline, this time on biotech financing. On your usual platforms including Spotify here: open.spotify.com/episode/19X27p…

‘VC가 한발 물러설 때 바이오 기업의 대체 자금원은? (Korean-language podcast)’ is on #SoundCloud on.soundcloud.com/sK25ksllC5XgsJ…

Experts discussed challenges and requirements around adoption of AI and big data tools in Korea's biopharma sector at a recent forum, amid a broader push towards an AI-powered economy by the country's new government, reports Pink Sheet, Citeline Regulatory. insights.citeline.com/pink-sheet/adv…

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Which Factors Are Key To Success? #Zydus #PharmaceuticalCompanies #business #research $GILD $IPN insights.citeline.com//scrip/r-and-d…

If you’re not using AI in trials yet, you’re already behind. Save your spot: vist.ly/46fg6 Join our webinar to see how AI and high-quality data is driving smarter trial design, better site selection, and faster decisions. September 24 | 10:00AM EST | 3:00PM BST

Multiple Korean ministries, biopharma companies, and other officials convened at a bio innovation roundtable to discuss strategies to emerge as a global biopharma powerhouse, Pink Sheet, Citeline Regulatory reports. insights.citeline.com/pink-sheet/r-a…

Interesting analysis by Xu Hu on another area where Chinese biopharma firms are steaming ahead and appear to be the main (if not first) players globally.

Japan Follows EU With Generics Exemption From US Tariffs insights.citeline.com//pink-sheet/ma…

Join Lisa Takagi in her latest Japanese-language mini #podcast, this episode on the EU and US pharma tariffs. On your usual platforms including Spotify below: open.spotify.com/episode/5GuNhT…

Trump: 100% tariff on any branded or patented pharma product unless manufacturing plant being built in the US. "Branded" definition needed before further comment. Wrote this before the announcement #tariff #BusinessNews #pharmatariff #Biotech insights.citeline.com//pink-sheet/ma…

Stonebridge Ventures’ managing director Hyun-Ki Kim talks to Scrip, Citeline Commercial on factors constraining the recovery of VC funding in Korean bioventures and its investment considerations, strategies and priorities. insights.citeline.com/scrip/leadersh…

Finance Watch: Job Cuts At Takeda, Bolt, Innate, X4 As Strategies Shift insights.citeline.com//scrip/finance…

Yuhan's R&D president talks to Scrip, Citeline Commercial about the leading Korean pharma firm’s open innovation strategy with Korean bioventures, as well as other strategies crucial for the company to transform into a major global player. insights.citeline.com/scrip/leadersh…

KIMCo CEO talks to Scrip, Citeline Commercial about how the Korean open innovation platform and life science accelerator and its member firms are notching up efforts to nurture Korean bioventures through the country’s first coalition fund. insights.citeline.com/scrip/leadersh…